Cytokinetics’ stock rockets to 19-year high after positive data on heart-disease treatment
Cytokinetics’ stock rocketed Wednesday, after the cardiovascular-biopharmaceutical company announced positive results from a Phase 3 trial of aficamten, a treatment for hypertrophic cardiomyopathy.